EN DE
STOCK COMPARISON

Laurus Labs vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Laurus Labs (LAURUSLABS) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Laurus Labs trades at ₹1,844 versus a fair value of ₹362 (-80%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).
Laurus Labs
LAURUSLABS.NSE · INR · Health Care
-80%
upside to fair value
overvalued
Price₹1,844
Fair Value₹362
Quality60/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-53%
upside to fair value
overvalued
Price¥54.62
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Laurus LabsJiangsu Hengrui Medicine Co
Valuation
94.7×P/E (TTM)43.6×
12.36×P/S (TTM)10.84×
15.89×P/B5.76×
47.6×EV/EBITDA33.0×
PEG0.93×
0.1%Dividend yield0.4%
₹2.00Dividend per share¥0.20
Profitability
13%Net margin25%
22%Operating margin32%
18%Return on equity15%
8%Return on assets9%
Growth
5%Revenue growth (YoY)13%
4.1%Avg. growth/yr (3Y)13.9%
7.2%Avg. growth/yr (5Y)2.5%
Balance & size
0.12×Debt / equity
$9BMarket cap$52B
mixedGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 2 to 10 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Laurus Labsof which business quality 59 · market factors 95 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 46
ProfitabilityMargins and returns on capital today
54
63
Quality GrowthAre margins and returns improving?
73
41
CashflowEarnings quality: real cash, not paper profit
47
82
Fin. StrengthBalance sheet, leverage, solvency risk
61
100
InvestmentDisciplined investing over empire-building
40
27
Low VolatilityCalm price path (market factor)
84
78
MomentumPrice trend over the last 3–12 months (market factor)
100
35
52W MomentumDistance to the 52-week high (market factor)
100
29
Net IssuanceBuybacks instead of dilution
81
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Laurus Labs

DCF Models₹361
Earnings-Based₹237
Dividend Discount₹30.53
Multiples₹332
Asset-Based₹65.73
Growth DCF₹271
Economic Profit₹230
Growth Earnings₹357

26 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Laurus Labs
Bear ₹186Fair Value ₹362Bull ₹464
₹1,844 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.62 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Laurus Labs · Health Care

Quality score60 · above median
Fair value upside-80% · bottom 25%

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-53% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Laurus Labs trades at ₹1,844 versus a fair value of ₹362 (-80%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.